Fig 1: TMPRSS11D was upregulated in human cervical cancer tissues and cell lines. (A and B) TMPRSS11D mRNA expressions in cervical cancer tissues and adjacent normal tissues. (C and D) The expression levels of TMPRSS11D at both mRNA and protein in four human cervical cancer cell lines. n = 3. *p < 0.05.
Fig 2: Inhibitory effects of TMPRSS11D knockdown were mediated by suppression of PI3K/Akt pathway in cervical cancer cells. (A) Expression levels of PI3K, p-PI3K, Akt, and p-Akt were measured using Western blot analysis at 24 h post transfection. (B) Cell proliferation of HeLa cells after IGF-1 treatment. (C) Cell migration of HeLa cells after IGF-1 treatment. n = 3. *p < 0.05 vs. si-NC group; #p < 0.05 vs. si-TMPRSS11D group.
Fig 3: Cell migration and invasion of cervical cancer cells were reduced after si-TMPRSS11D transfection. Cell migration and invasion were measured using transwell assays at 24 h post transfection. (A and B) Cell migration of cervical cancer cells. (C and D) Cell invasion of cervical cancer cells. n = 4. *p < 0.05.
Fig 4: Knockdown of TMPRSS11D promotes the apoptosis of cervical cancer cells. Cell apoptosis were detected through PI staining and the Annexin V method after transfection with si-TMPRSS11D or si-NC, followed by flow cytometry. (A) Figure was obtained from CaSki cells; (B) figure was obtained from HeLa cells. n = 4. *p < 0.05.
Fig 5: EMT phenotype of cervical cancer cells was prevented by si-TMPRSS11D transfection. After 24 h post transfection, the expression levels of EMT markers including E-cadherin, N-cadherin, and fibronectin in CaSki (A) and HeLa cells (B) were measured using Western blot analysis. n = 4. *p < 0.05.
Supplier Page from Abcam for Anti-TMPRSS11D antibody